Spesolimab in Pyoderma Gangrenosum

NCT06092216 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped The funding sponsor terminated our study and will conduct a multicenter national study in its place.

Conditions

Pyoderma Gangrenosum

Interventions

DRUG: Spesolimab

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]